biostudies-literatureUnknown9(6)Li Y<h4>Importance</h4>Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).<h4>Objective</h4>To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).<h4>Design, setting, and participants</h4>This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantationJAMA cardiology523-531https://www.ebi.ac.uk/biostudies/studies/S-EPMC11024736biostudies-literatureExtended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.PMC11024736Hu TZhang JGuo YHu XShen CZhang RSu GShi XZhang PGuo JShou XSu XYuan ZJin LZheng ZZheng YZeng QJin QAn JZeng YJin YZeng CAngiolillo DJHe SFeng LQiao SZeng HJiang DQin QHan YHan ZZhao XStone GWQu PFan JZhao RZhao GSui LKong LCheng BZhou YZhou XZhu JShi HWang BWang CCong HWang FPei HWang HDu ZQiu MWu GWang JGao CWang LWu HChen ZOPT-BIRISK InvestigatorsSun FChen XChen SWu WWang ZLi JLi CYang MChen HZhong ZLi LLi NLi XLi YLi SLi TYang PYang QMi JLiu JMa LJing QMa YJiang YLiu XLiu YJiang WXu BGong JTao JHou ARu LHou PYin DZhang ZZhang YLiu ALiu BLuo YMa GLiu GfalseExtended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.<h4>Importance</h4>Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).<h4>Objective</h4>To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).<h4>Design, setting, and participants</h4>This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation2024-01-01T00:00:00Z2024 Jun2026-06-01T13:05:16.297Z2025-07-14T03:02:48.47ZS-EPMC110247363863048910.1001/jamacardio.2024.0534